← Back to Screener
ZOETIS INC. (ZTS)
Price$122.72
Favorite Metrics
Price vs S&P 500 (26W)-20.62%
Price vs S&P 500 (4W)-1.64%
Market Capitalization$51.58B
P/E Ratio (Annual)19.30x
Indicated Dividend Yield (Annual)1.64%
All Metrics
P/CF (Annual)17.76x
Book Value / Share (Quarterly)$7.84
P/TBV (Annual)23.77x
Indicated Dividend (Annual)$2.00
Revenue Growth (3Y)5.42%
Cash Flow / Share (Quarterly)$5.37
Payout Ratio (TTM)33.26%
Price vs S&P 500 (YTD)-6.39%
Gross Margin (TTM)71.89%
Net Profit Margin (TTM)28.23%
EPS (TTM)$6.02
10-Day Avg Trading Volume3.22M
EPS Excl Extra (TTM)$6.02
Revenue Growth (5Y)7.24%
EPS (Annual)$6.02
Dividend / Share (Annual)$2.04
ROI (Annual)21.59%
Gross Margin (Annual)71.92%
Net Profit Margin (5Y Avg)26.98%
Cash / Share (Quarterly)$5.44
P/E Basic Excl Extra (TTM)19.30x
Revenue Growth QoQ (YoY)3.02%
EPS Growth (5Y)11.97%
P/E Normalized (Annual)19.30x
ROA (Last FY)17.28%
Revenue Growth TTM (YoY)2.28%
EBITD / Share (TTM)$8.25
ROE (5Y Avg)54.42%
Operating Margin (TTM)35.49%
Cash Flow / Share (Annual)$5.37
P/B Ratio15.48x
P/B Ratio (Quarterly)16.65x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)6.16x
Net Interest Coverage (TTM)15.44x
ROA (TTM)18.06%
EPS Growth QoQ (YoY)6.75%
EV / EBITDA (TTM)15.92x
EPS Incl Extra (Annual)$6.02
Current Ratio (Annual)3.03x
Quick Ratio (Quarterly)1.94x
3-Month Avg Trading Volume4.61M
52-Week Price Return-17.45%
EV / Free Cash Flow (Annual)25.54x
P/E Incl Extra (TTM)19.30x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$5.49
P/S Ratio (Annual)5.45x
Asset Turnover (Annual)0.61x
52-Week High$172.23
Operating Margin (5Y Avg)33.71%
EPS Excl Extra (Annual)$6.02
CapEx CAGR (5Y)6.51%
Tangible BV CAGR (5Y)2.53%
26-Week Price Return-13.74%
Quick Ratio (Annual)1.94x
13-Week Price Return-2.04%
Total Debt / Equity (Annual)2.72x
Current Ratio (Quarterly)3.03x
Enterprise Value$58,309.035
Revenue / Share Growth (5Y)8.87%
Asset Turnover (TTM)0.64x
Book Value / Share Growth (5Y)-0.24%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)1.12x
Pretax Margin (Annual)35.49%
Cash / Share (Annual)$5.44
3-Month Return Std Dev26.00%
Gross Margin (5Y Avg)70.68%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)8.85%
EBITDA Interim CAGR (5Y)9.82%
ROE (Last FY)80.25%
Net Interest Coverage (Annual)12.66x
EPS Basic Excl Extra (Annual)$6.02
P/FCF (TTM)22.59x
Receivables Turnover (TTM)6.52x
EV / Free Cash Flow (TTM)25.54x
Total Debt / Equity (Quarterly)2.71x
EPS Incl Extra (TTM)$6.02
Receivables Turnover (Annual)6.52x
ROI (TTM)22.45%
Dividend Growth Rate (5Y)20.56%
P/S Ratio (TTM)5.45x
Pretax Margin (5Y Avg)33.71%
Revenue / Share (Annual)$21.33
Tangible BV / Share (Annual)$5.49
Forward P/E20.37x
Free OCF CAGR (5Y)6.41%
Price vs S&P 500 (52W)-52.09%
P/E Ratio (TTM)19.30x
EPS Growth TTM (YoY)10.17%
Year-to-Date Return-2.46%
5-Day Price Return1.33%
EPS Normalized (Annual)$6.02
ROA (5Y Avg)15.99%
Net Profit Margin (Annual)28.23%
Month-to-Date Return3.82%
Cash Flow / Share (TTM)$5.96
EBITD / Share (Annual)$8.25
EPS Growth (3Y)10.25%
Operating Margin (Annual)35.49%
LT Debt / Equity (Annual)2.71x
P/CF (TTM)17.76x
ROI (5Y Avg)19.84%
P/E Excl Extra (TTM)19.30x
LT Debt / Equity (Quarterly)2.71x
EPS Basic Excl Extra (TTM)$6.02
P/TBV (Quarterly)23.77x
Payout Ratio (Annual)33.26%
P/B Ratio (Annual)16.65x
Dividend / Share (TTM)$2.04
Inventory Turnover (TTM)1.12x
Pretax Margin (TTM)35.49%
Book Value / Share (Annual)$7.84
Price vs S&P 500 (13W)-4.42%
Net Margin Growth (5Y)2.84%
Dividend Yield (TTM)1.72%
Beta0.93x
P/FCF (Annual)22.59x
Revenue / Share (TTM)$21.59
ROE (TTM)58.23%
52-Week Low$113.29
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.96
3.92
3.88
3.84
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ZTSZOETIS INC. | 5.45x | 2.28% | 71.89% | 11.97% | $122.72 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Zoetis is the global leader in animal health, offering vaccines, diagnostics, parasiticides, and anti-infectives for both companion and production animals. The company generates approximately 65% of revenue from companion animal products (dogs, cats, horses) and 35% from production animal health (cattle, pigs, poultry), with domestic operations tilted toward companion animals and international operations toward production animals. Spun from Pfizer's animal health unit, Zoetis holds the largest market share in the industry.